{
  "id": "602c1c701cb411341a00011d",
  "type": "summary",
  "question": "What did the RESILIENT study investigate?",
  "ideal_answer": "A global, randomized, double-blind placebo-controlled study was conducted to confirm that BYM338 (bimagrumab), an anti-activin type II receptor antibody, improves motor function in patients with sporadic inclusion body myositis after 52 weeks' treatment consisting of intravenous administration every 4 weeks at doses of 10, 3, and 1\u2005mg/kg.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31761834"
  ],
  "snippets": [
    {
      "text": "A global, randomized, double-blind placebo-controlled study was conducted to confirm that BYM338 (bimagrumab), an anti-activin type II receptor antibody, improves motor function in patients with sporadic inclusion body myositis after 52 weeks' treatment consisting of intravenous administration every 4 weeks at doses of 10, 3, and 1\u2005mg/kg. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31761834",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}